Published in Int J Organ Transplant Med on January 01, 2012
Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells. Viral Immunol (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Infection in organ-transplant recipients. N Engl J Med (1998) 6.49
Infection in solid-organ transplant recipients. N Engl J Med (2007) 5.47
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant (2010) 3.35
A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med (1989) 2.78
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med (1999) 2.33
Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant (2008) 2.07
Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis (1990) 1.96
Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int (2004) 1.57
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation (2012) 1.56
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant (2006) 1.52
Primary cytomegalovirus and opportunistic infections. Incidence in renal transplant recipients. JAMA (1978) 1.24
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant (2007) 1.24
Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation (1993) 1.18
Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation (1992) 1.16
Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 1.01
The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation (1992) 0.98
Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation (1997) 0.95
Cytomegalovirus infection and indirect sequelae in the immunocompromised transplant patient. Transplant Proc (1991) 0.92
Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transplant Proc (1991) 0.92
Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc (2001) 0.90
Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol (1996) 0.82
Prevention of cytomegalovirus disease in renal transplantation: single-center experience. Transplant Proc (2009) 0.81
Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients. Transpl Int (1994) 0.79